The Law Offices of Frank R. Cruz announces an investigation of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On May 1, 2025, Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months, citing additional time required to review newly submitted Risk Evaluation and Mitigation Strategy (REMS). The Company further revealed that, “following pre-NDA discussions with FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for aficamten in oHCM without an accompanying REMS.”

On this news, Cytokinetics’s stock price fell $5.57, or 12.9%, to close at $37.35 per share on May 2, 2025, thereby injuring investors.